230 related articles for article (PubMed ID: 9372899)
1. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
2. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Partin AW; Getzenberg RH; CarMichael MJ; Vindivich D; Yoo J; Epstein JI; Coffey DS
Cancer Res; 1993 Feb; 53(4):744-6. PubMed ID: 7679049
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.
Subong EN; Shue MJ; Epstein JI; Briggman JV; Chan PK; Partin AW
Prostate; 1999 Jun; 39(4):298-304. PubMed ID: 10344220
[TBL] [Abstract][Full Text] [Related]
4. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
[TBL] [Abstract][Full Text] [Related]
5. Human prostate tissue antigens defined by murine monoclonal antibodies.
Starling JJ; Sieg SM; Beckett ML; Wirth PR; Wahab Z; Schellhammer PF; Ladaga LE; Poleskic S; Wright GL
Cancer Res; 1986 Jan; 46(1):367-74. PubMed ID: 2415250
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen.
Bazinet M; Cote RJ; Cordon-Cardo C; Myc A; Fair WR; Old LJ
Cancer Res; 1988 Dec; 48(23):6938-42. PubMed ID: 2460231
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity: a prevalent marker of malignant human prostate tissue.
Sommerfeld HJ; Meeker AK; Piatyszek MA; Bova GS; Shay JW; Coffey DS
Cancer Res; 1996 Jan; 56(1):218-22. PubMed ID: 8548767
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Horoszewicz JS; Kawinski E; Murphy GP
Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
12. Characterization of reactivity of monoclonal autoantibodies with renal antigens in experimental lupus nephritis.
Kootstra JC; Veninga A; Baelde JJ; van Eendenburg J; de Heer E; Bruijn JA
J Clin Lab Immunol; 1996; 48(5):201-18. PubMed ID: 9394243
[TBL] [Abstract][Full Text] [Related]
13. [Study of growth fraction on fine needle aspirated prostatic tissue smear using monoclonal antibody Ki-67].
Sai S; Takashi M; Miyake K; Koshikawa T
Hinyokika Kiyo; 1991 Aug; 37(8):881-6. PubMed ID: 1957731
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer.
DuHadaway JB; Lynch FJ; Brisbay S; Bueso-Ramos C; Troncoso P; McDonnell T; Prendergast GC
J Cell Biochem; 2003 Feb; 88(3):635-42. PubMed ID: 12532338
[TBL] [Abstract][Full Text] [Related]
15. Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage.
Lakshmanan Y; Subong EN; Partin AW
J Urol; 1998 Apr; 159(4):1354-8. PubMed ID: 9507883
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
Hudolin T; Juretic A; Spagnoli GC; Pasini J; Bandic D; Heberer M; Kosicek M; Cacic M
Prostate; 2006 Jan; 66(1):13-8. PubMed ID: 16114059
[TBL] [Abstract][Full Text] [Related]
17. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
18. Loss of uteroglobin expression in prostate cancer: relationship to advancing grade.
Weeraratna AT; Cajigas JA; Schwartz A; Enquist EG; Manyak MJ; Patierno SR
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2295-300. PubMed ID: 9815627
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
